BBOT

BridgeBio Oncology Therapeutics Inc. NASDAQ Listed Aug 12, 2025

Healthcare ·Biotechnology ·US · bbotx.com

$4.66

After hrs $4.90 +5.15%

Mkt Cap $373.3M

52w Low $4.59 0.6% of range 52w High $14.87

50d MA $8.19 200d MA $9.44

P/E (TTM) —

EV/EBITDA —

P/B 0.3x

Debt/Equity 0.0x

ROE -32.6%

P/FCF -1.3x

RSI (14) 8.30

ATR (14) $0.57

Beta 0.51

50d MA $8.19

200d MA $9.44

Avg Volume 522.7K

BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.

SIC Code

2834

CIK (SEC)

1869105

Phone

650 405 4770

256 E. Grand Avenue · South San Francisco, CA 94080 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Aug 11, 2026	AMC	-0.56	-0.71	-24.8%	9.20	-1.4%	+2.4%	-2.0%	-1.8%	-0.2%	-1.0%	—
May 12, 2026	AMC	-0.51	-0.48	+6.3%	8.13	-1.7%	-0.6%	+5.3%	+0.0%	+2.8%	-0.3%	—
Mar 5, 2026	AMC	-0.63	-0.49	+22.6%	9.89	+5.7%	+5.4%	-1.1%	-1.2%	-2.0%	-8.6%	—
Nov 12, 2025	AMC	-0.38	-1.03	-169.9%	12.63	+0.4%	-2.0%	+6.0%	+4.6%	-1.8%	-5.9%	—
Aug 1, 2025	AMC	-42.45	-50.34	-18.6%	10.43	+1.8%	-8.9%	-3.7%	+8.1%	+1.1%	+0.6%	—
May 15, 2025	AMC	—	-52.15	—	10.85	+0.2%	+0.0%	+0.0%	+0.0%	-0.3%	+0.0%	—
Mar 11, 2025	AMC	—	0.12	—	10.70	+0.0%	+0.2%	+0.7%	-0.2%	-0.2%	+0.0%	—
Nov 14, 2024	AMC	—	-0.74	—	10.53	+0.3%	+0.5%	-1.5%	+0.0%	+0.0%	+0.0%	—
Aug 14, 2024	AMC	—	0.09	—	10.40	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	-0.1%	—
May 15, 2024	AMC	—	0.05	—	10.34	+0.0%	+0.0%	+0.0%	+0.0%	-0.9%	+0.0%	—
Dec 31, 2023	AMC	—	-0.00	—	—	—	—	—	—	—	—	—
Dec 31, 2022	AMC	—	-0.00	—	—	—	—	—	—	—	—	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Jul 8	JP Morgan	Initiates	Overweight	$27	$8.29	$8.93	+7.7%	+8.8%	+0.8%	-8.5%	+2.4%	+3.5%
Jun 22	Oppenheimer	Reiterates	Outperform	$22	$7.56	$7.73	+2.2%	+4.1%	-4.7%	-0.8%	+3.4%	-3.8%
May 11	Canaccord Genuity	Initiates	Buy	$23	$7.66	$7.85	+2.5%	+3.0%	+3.0%	-0.6%	+5.3%	+0.0%
Mar 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.89	$10.45	+5.7%	+5.4%	-1.1%	-1.2%	-2.0%	-8.6%
Dec 11	Wedbush	Maintains	Outperform → Outperform	—	$12.88	$12.98	+0.8%	-0.3%	-1.9%	-4.7%	-1.2%	-3.5%
Nov 25	Wedbush	Maintains	Outperform → Outperform	—	$12.29	$12.44	+1.2%	+0.6%	-1.5%	+1.1%	-0.8%	-7.0%
Nov 13	Oppenheimer	Maintains	Outperform → Outperform	—	$12.63	$12.68	+0.4%	-2.0%	+6.0%	+4.6%	-1.8%	-5.9%

Institutional (13F) — Top 0 All ↗

No 13F holders found.

Mutual Funds / ETFs (N-PORT) — Top 3 All ↗

#	Fund	Shares	Value	Period
1	BlackRock Health Sciences Opportunities Portfolio	673,766	$6M	May 2026
2	Small Cap Core Fund	15,579	$119K	Jun 2026
3	iShares Morningstar Small-Cap ETF	2,699	$32K	Jan 2026

Data updated apr 24, 2026 8:44pm · Source: financialmodelingprep.com